Category: Startups

Innovaccer Dives Into AI With Series F Raise

Posted on by Jason Barry

We’re barely halfway through the first month of 2025, and Innovaccer already raked in what could end up being the biggest raise of the year with its $275M Series F funding round.

Innovaccer got its start in 2014 with the goal of breaking down healthcare’s data siloes and using that connected fabric of information to improve care delivery. 

  • That infrastructure was made possible by Innovaccer’s Data Activation Platform, which unifies data across EHRs and care settings to deliver insights at the point of care. 
  • Innovaccer’s Health Cloud adds an entire suite of applications on top of that data layer to modernize patient experiences and alleviate administrative burdens for providers.

If Innovaccer’s last chapter was about building the infrastructure to make AI possible, the next part of its story will revolve around spearheading that new wave of solutions.

  • Innovaccer plans to introduce a bustling ecosystem of AI co-pilots and agents to its portfolio, tackling everything from prior authorization and clinical decision support to care management and contact centers. 

By throwing its hat into the ring of so many different segments, Innovaccer will be facing competition from just as many directions.

  • The health analytics arena is packed with players like Health Catalyst and Databricks. New AI scribing and revenue cycle management startups get funded every week. Customer relationship management has a 1000-pound gorilla named Salesforce.
  • The key to Innovaccer’s success will be its breadth of services, and it’s tough to name a single competitor that can match the same level of data infrastructure and co-pilot ecosystem needed to scale AI across large orgs without a mess of point solutions.

The Takeaway

Healthcare organizations have spent decades digitizing enormous amounts of data, but none of them actually want a mountain of data – they want the insights buried within it. Innovaccer helped lead the charge on creating the infrastructure, now it’s building the AI applications that can showcase the new experiences it made possible.

Transcarent Builds Benefits Behemoth With Accolade Acquisition

Posted on by Jason Barry

It’s already shaping up to be a huge year for digital health M&A, and the headlining announcement from our action-packed first week was Transcarent’s acquisition of publicly traded benefits rival Accolade.

The $621M price tag is undeniably a big move for Transcarent, which launched in 2020 to make it easier for employees to access all of their care needs through a single convenient interface, their smartphone.

  • The platform connects members to comprehensive experiences including Cancer Care, Weight Health, and Surgery Care (through provider partnerships), while also simplifying how employers manage and track that care.
  • Transcarent recently landed $126M in Series D funding at a $2.2B valuation, which it earmarked for AI innovations like its new WayFinding solution, and for taking advantage of juicy M&A opportunities in beaten-down competitors.

Accolade is a personalized health and benefits company with a long list of offerings that includes virtual-first primary care, navigation services, and expert medical opinions.

  • Despite raising $220M during its 2020 IPO, Accolade turned into an attractive acquisition target after struggling with revenue growth and booking a $100M loss during the latest fiscal year.
  • Accolate will add over 1,000 clinicians to Transcarent’s team, as well as deep data integrations with a wide partner ecosystem across diabetes, mental health, fertility, and MSK care.

Transcarent now plans to fold Accolade into its existing platform, bringing together the “best of provider, partner, and payor ecosystems.” 

  • By integrating its WayFinding and comprehensive care experiences with Accolade’s expert medical opinions and primary care, Transcarent expects to drive higher utilization and lower costs (+Accolade’s 16 years of health data for AI training was a nice kicker).

The Takeaway

At a time when point solution fatigue is crippling employers and public healthcare companies have lagged behind the broader market rally, Transcarent’s acquisition of Accolade seems like the right move at the right time. It could also mark the beginning of a much bigger M&A wave in digital health, especially if valuations continue looking too appetizing to pass up.

Redesign Raises $175M Venture Building Fund

Posted on by Jason Barry

Launching a healthcare company is hard. Launching dozens of them is even harder, but that’s exactly what Redesign Health plans to do after raising $175M for its largest fund to-date.

Redesign isn’t a venture capital firm, although it’s funded more digital health startups than most VCs. It’s not an accelerator, yet it’s launched more companies in the past six years than most pure startup studios.

Then what is it? Redesign is a “venture builder” that’s cultivated over 60 healthcare companies by supporting founders across three key areas:

  • Redesign’s hands-on approach starts with an in-house research lab / analyst team that helps look into sectors, identify challenges, and validate business cases.
  • An established network of relationships with health systems, payors, and other health tech companies gives founders an accelerated path to commercial traction.
  • Redesign equips startups with operational resources ranging from executive placements to branding services to fine-tune operations throughout every stage of growth.

The new fund will allow Redesign to partner on companies at the intersection of technology and the investment themes where it believes “innovation can drive the greatest impact”:

  • Addressing the healthcare labor shortage
  • Accelerating value-based and longitudinal care
  • Advancing healthcare interoperability
  • Preparing for an aging population
  • Eliminating barriers to health equity
  • Expanding sites of care
  • Growing the insured population
  • Driving healthcare personalization and consumerization

Since getting its start in 2018, Redesign’s portfolio has reached more than 15M patients and generated over $1B in revenue, producing some big name players like metabolic health startup Calibrate and VBC cardiology company CardioOne (acquired by WindRose earlier this year).

  • There’s been a few bumps along the way – including layoffs as Redesign slowed its launch pace to weather the post-pandemic downturn – but the new fund is a good sign that it expects smoother sailing from here.

The Takeaway

Healthcare startups have high upfront capital requirements, steep steps between business stages, and difficulty recruiting the seasoned executives needed to reach scale. Although those problems will never magically disappear, Redesign now has a $175M magic wand to make them a whole lot more manageable.

Soda Health Cracks Open $50M of Funding

Posted on by Jason Barry

Soda Health is cracking open $50M of Series B funding to shake up supplemental benefits.

Medicare Advantage plans deliver $131B/year in benefit funds for transportation, fitness, and grocery programs – yet the impact often falls flat due to an outdated tech infrastructure that makes it difficult for members to take advantage of their benefits.

Soda’s Smart Benefits platform unlocks the full potential of these programs by rebuilding their core infrastructure with a modern payments stack and an expansive retail network:

  • Members get a user-friendly way to understand where and how to use their benefits.
  • Payors can scale benefit programs supported by Soda’s network of 50k retail locations (including Kroger, Albertsons, CVS) to optimize utilization and lift STAR ratings.
  • Retailers get more member traffic to offer health products, food, and pharmacy services.

The secret ingredient is the retail network, which provides the data underpinning Soda’s biggest differentiator: personalized patient engagement. 

  • Soda’s “first-of-its-kind open loop fintech infrastructure” tracks item-level purchases in real time, allowing it to reward members for using their benefit dollars on products approved to fill gaps in their care.
  • By connecting supplemental benefits with insights from retail data, Soda is uniquely positioned to deliver tailored outreach for closing care gaps (by encouraging preventative screenings, improving medication adherence, etc.).

The fresh funds will accelerate Soda’s expansion into new CMS-compliant benefit categories and add some extra fizz to its gap closure strategies, which will reportedly allow it to enter risk-based structures with MA and Medicaid plans.

The Takeaway

Soda isn’t here to build a better supplemental benefits platform, it’s here to rebuild the category from the ground up using a stronger infrastructure of retail partners, patient engagement, and care gap closure. Climbing utilization trends and dwindling capitation rates are pressuring MA plans from multiple fronts, so the time is right for a refreshing approach.

Oura Lands $75M From Dexcom to Bring Smart Rings to Healthcare

Posted on by Jason Barry

Smart ring maker Oura is taking the leap into healthcare, and it just landed a major investment from Dexcom to help it cross the chasm.

Things are looking up for the creator of the Oura Ring. In just the last week:

  • Oura entered a strategic partnership with continuous glucose monitoring giant Dexcom, who also handed it $75M in Series D funding and vaulted its valuation to a whopping $5B.
  • The release of Oura’s Perimenopause Report was well-received for including a trove of hard-to-capture data and highlighting gaps in women’s health research.
  • Apple squashed rumors that it was developing its own smart ring, meaning that the category dodged the same bullet that saw Apple steal nearly half of the headphone market overnight when it first launched the AirPods.

Oura got its start in 2013 helping health-conscious consumers optimize their performance with insights into areas like sleep quality and heart rate variability.

  • It’s since shipped 2.5 million of its flagship Oura Ring and expects annual revenue to double to $500M before the end of 2024.
  • Within the last year, Oura also began making a string of acquisitions to support its user base along more parts of their health journey, picking up both Sparta Science (data analytics) and Veri (glucose monitoring and meal timing insights).

Dexcom is hot on the heels of releasing its first over-the-counter Stelo CGM for prediabetic populations, which already has 70k users and is reportedly a “gateway product” to expand into the broader metabolic health market.

  • The Oura partnership will enable two-way data flow between Dexcom biosensors and Oura wearables to provide “a first-of-its-kind metabolic health management experience,” with the first app integration expected in the first half of next year.
  • The duo will also be co-marketing and cross-selling each other’s products to attract new customers who want to better understand the link between sleep, activity, nutrition, and their glucose.

The Takeaway

Oura has been looking to support its massive user base with deeper insights into their overall health, and Dexcom has been searching for ways to get its glucose monitoring devices in front of a non-diabetic audience. This seems like a match made in heaven.

Babylon Founder Returns With Launch of Quadrivia

Posted on by Jason Barry

Babylon founder Ali Parsa is rising from the wreckage with a new startup – Quadrivia – and he’s certainly hoping that his second AI wonder app works out better than his first.

A LinkedIn post from Parsa laid out Quadrivia’s vision of using customizable AI agents to tackle “the main challenge” in healthcare: the structural imbalance between the elastic demand from our communities and the constrained supply of our clinicians.

  • Quadrivia’s undisclosed amount of seed funding was enough to kick off beta testing for Qu, a clinical assistant with “wide-ranging capabilities across the care spectrum.”
  • Qu’s agents have the lofty goal of assisting clinicians across the full stack of routine clinical and administrative tasks, patient interactions, decision-making, chronic and postoperative care, and continuous monitoring. 

Qu’s ambitious scope is reportedly made possible by its dual architecture: “System 1 includes tasks that rely on quick decision-making, such as answering direct questions. System 2 involves more complex tasks, like assessing patient symptoms and considering multiple diagnoses.”

  • These capabilities are supported by the patient’s EHR data (still working out the details), natural language conversations (but not real time), and a large clinical knowledge base (unclear from where).

The backstory of Quadrivia is inextricably linked to the backstory of Babylon, which has been called everything from the “future of the NHS” to “the Madoff of digital health.”

  • The grand promises of Babylon’s AI chatbot rhymed with the goals Qu outlined above, which was enough to fuel a $4.2B public market debut in 2021.
  • By this time last year, what we’ll call “difficulty living up to those promises” had Babylon shares trading at pennies, and it filed for bankruptcy in the U.S. after an odd takeover from digital therapeutics developer MindMaze turned out to be too good to be true.

The Takeaway

If Quadrivia is to succeed where Babylon failed, it’ll need a strategy that shores up the holes in its predecessor’s approach. That means peer-reviewed research, independent validation, and consistent messaging about Qu’s capabilities… and limitations.

Bessemer’s Key Benchmarks for Health Tech

Posted on by Jason Barry

Bessemer Venture Partners put out an update to its top-tier blog series on benchmarks that health tech startups can use to see how they stack up against the competition.

We won’t dive into the full industry overview, but here’s a look at a few of the key metrics Bessemer shared to illustrate how the health tech segment has evolved since last year.

Graduating is hard. Health tech “graduation rates” from Seed to Series A and B have fallen significantly compared to previous cohorts.

  • Of the companies closing Series A rounds, the median time it takes to reach that milestone is 50% longer in 2024 than prior years, and is longer in health tech than any other sector.

We’re so back. Although the funding environment remains challenging, the good news for those that are able to raise capital is that valuations have rebounded to peak levels.

  • “Phoenix” companies that have risen from the ashes of the market correction are commanding premium valuations in massive late stage rounds (see Equip and Maven), while frothy investments in AI startups are fueling an early stage boom.

The AI factor can’t be ignored. The share of health tech investment directed at AI-focused companies has increased by 9 percentage points in just two years – hitting 38% in 2024.

  • These startups are reaching 30-50x ARR multiples, with valuations 2-5x higher than their non-AI counterparts.

Services-as-Software is the new paradigm. These businesses use AI to automate workflows historically performed by humans, and benchmarks show an accelerated go-to-market trajectory compared to traditional SaaS models. 

  • Services-as-Software companies are reaching $10M ARR at unprecedented speeds as the industry rushes to test if they can deliver on their value promises, and the following chart has the full breakdown – at least for the readers that know their finance acronyms.

The Takeaway

Bessemer’s full post goes much deeper on the overall health tech landscape and the intricacies of AI Services-as-Software, but the four charts above give you a solid lay of the land. Bessemer remains as optimistic as ever on health tech heading into 2025, and it’s definitely impressive to see the resilience that these companies have showcased over the last year.

CopilotIQ and Biofourmis Merge to Build Single Pane Home Care

Posted on by Jason Barry

One of the biggest stories to come out of last week’s HLTH meetup was the surprise merger between Biofourmis and its under-the-radar remote care competitor CopilotIQ.

CopilotIQ launched a few short years ago in 2021 to provide remote patient monitoring for seniors managing chronic conditions through its High-Frequency Connected Care platform.

  • The platform combines clinical automation software with biomarker data, behavioral analytics, and nursing visits to better manage conditions like diabetes and hypertension.
  • The company has raised just $30M to-date, and was mostly operating in stealth as it grew its footprint to 11 states and “tens of thousands” of patients.

Biofourmis on the other hand is a Softbank-backed giant that reached unicorn status in 2022 as it closed its $300M Series D round, although we haven’t seen an update on that peak-pandemic valuation.

  • The focus for Biofourmis has centered on supporting health systems, payors, and pharma companies with in-home delivery of complex care using wearables, FDA-cleared algorithms, and a virtual specialty care ecosystem.
  • Its founder-CEO Kuldeep Rajput departed last year and recently transferred his shares to existing investors while launching a multimodal clinical AI startup called OutcomesAI.

The combined company will be helmed by CopilotIQ CEO David Koretz, who will oversee its transformation into an end-to-end home care solution across the full spectrum from pre-surgical optimization to acute, post-acute, and chronic care.

  • The announcement highlights the power of combining CopilotIQ’s consumer-facing business with Biofourmis’s enterprise customer expertise within a “single pane of glass” to view patients across the entire care continuum.
  • Tough to argue with the logic behind one integration, one security audit, simplified procurement, and a better user experience.

Outside of that, the only other info on the merger is that it’s an all-stock transaction that’ll see existing investors – including General Atlantic and Bessemer Venture Partners – pile in another $100M to attempt to bridge the gap to the public markets.

The Takeaway

At a time when valuations are quickly heading back to earth and exits are hard to come by, Biofourmis and CopilotIQ’s merger has all the tell-tale signs of an investor-driven union, and the smaller company’s CEO will now get a shot at proving platforms beat point solutions for in-home care.

Oshi Lands $60M Series C for Virtual GI Care

Posted on by Jason Barry

Oshi Health just found 60 million reasons why becoming the first virtual gastrointestinal center of excellence in the U.S. was a great decision.

Since launching in 2020, Oshi has raised nearly $120M (half from its just-closed $60M Series C) to help the ~70M Americans suffering from GI conditions control their symptoms while decreasing their total cost of care.

  • It accomplishes this by supporting patients with a gastroenterologist-led care team of advanced practice providers, dietitians, behavioral health specialists, and care coordinators.
  • These multidisciplinary teams collaborate with local PCPs and GI clinics to treat conditions ranging from acid reflux to Crohn’s Disease, enabling a high-touch point approach that would be difficult to achieve without the extra bandwidth.

The fact that Oshi is already available in all 50 states and to 40M+ people as an in-network benefit is a testament to both the size of the market as well as its model, which differentiates itself with its deep behavioral health integration.

  • Many symptoms can be caused by the connection between the patient’s gut and brain, with trauma often marking the onset of new GI issues, and can be corrected through CBT or gut-directed hypnotherapy. Oshi has the research to back that up.

A study done in conjunction with a large national health plan found that Oshi generated $10,292 per patient in avoidable testing, procedures, and ED visits, with 92% of patients reporting symptom improvement within six months.

  • Publishing this data was instrumental to Oshi securing health plan coverage, which made it easier for the employers they work with to integrate that care into their benefits offerings, and in turn helped drive awareness among employees with access to the service.

Although payors and employers continue to shift away from specialty point solutions toward broader digital health platforms, the GI market is large enough to justify standalone companies like we see in cardiology or MSK.

The Takeaway

Oshi has quickly emerged as a leader in the virtual GI space, and it’s now armed with $60M to push its lead even further by expanding its payor coverage, provider group partnerships, and employer programs – not to mention a push into Medicare slated for 2025.

Maven Clinic, Suki, Glooko Start Q4 in Style

Posted on by Jason Barry

It isn’t every week we see digital health startups score a hat trick of massive funding rounds – let alone one that rakes in a combined $295M – but Maven Clinic, Suki, and Glooko clearly came to play.

Maven Clinic kicked off the action by closing $125M of Series F funding and vaulting its valuation to $1.7B. The women’s and family health startup also gave us a behind-the-scenes peek at its 10-year roadmap:

  • Fertility Benefits – Maven’s fertility benefits administration product has brought millions of lives under management since launching last year, and it’s leaning in on forming more clinic partnerships to create a seamless experience between Maven’s virtual care model, financial platform, and in-person treatments. 
  • VBC – The maternity program that serves as the bedrock of Maven’s platform is moving past “phase one” by using real-time data to engage members with a broader ecosystem of services, enabling Maven to take on full-risk and align incentives with outcomes.
  • Engagement – Soon-to-be-announced AI capabilities will bolster Maven’s engagement engine with more insights into fertility, maternity, and family building, as well as often-overlooked areas like return-to-work, parenting, and menopause.

Next up we saw ambient AI startup Suki land $70M of Series D financing on the heels of  adding over a dozen new health systems in the past few months.

  • The release highlighted an expanded partnership with MedStar Health that’ll make Suki Assistant available to thousands of clinicians across specialties including primary care, cardiology, and gastroenterology.
  • Suki also teased plans to expand beyond its existing Suki Assistant and Suki Platform offerings, although details were sparse on what that might entail.

Glooko rounded out last week’s top scorers with a $100M Series F round and the appointment of a new CEO to guide the digital diabetes developer through its next chapter.

  • Freshly appointed chief Mike Alvarez will accelerate the global expansion of Glooko’s solution suite that helps diabetics take control of their condition and equips care teams with a unified platform for managing devices, data, and engagement.

The Takeaway

Digital health startups are off to a hot start in Q4, and Maven Clinic, Suki, and Glooko are the ones cranking up the heat. All signs are pointing to more late-stage mega-rounds as companies look to shore up their balance sheets and bridge the gap to a quickly thawing IPO market, unless of course they’re already eager to diveright in.

Get the top digital health stories right in your inbox

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Digital Health Wire team

You're all set!